In partnership with
OVERVIEW
Happy Saturday
Welcome to the Stocktwits Top 25 Newsletter this week!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
How do you Feel about the Market Right Now?
Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵💫
Here are the Stocktwits Top 25 Lists for this week:
S&P 500
ST Top 25 S&P 500 💪
The playbook for how staff engineers actually operate
You're already doing staff-level work. Someone with half your skill just got the title instead.
The difference isn't the code. It's knowing how the role actually works.
Sign up for The Code newsletter and get:
The complete staff engineer playbook, 6 modules and 25 lessons on scope, sponsors, and the promotion packet that proves you're ready
The Code newsletter (5 min daily) so you keep leveling up. The playbook is just the beginning.
NASDAQ 100
The Large-Cap Nasdaq 100 🤖
RUSSELL 2000
The Growth-Centric Russell 2000 🦐
PRESENTED BY
*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Mid-Cap / Micro-Cap Top Movers of the Week 🐶
Healthcare dominates the Russell 2000 momentum list, but earnings and clinical follow-through will decide which rank gains stick.
$MANE ( ▲ 0.21% ) : Veradermics, Russell 2000 No. 11 → 6: The biggest rank climber gained just 0.2% this week after Monday’s positive Phase 3 results for its oral hair-loss treatment. Risk: Twelve-month safety data are expected later in 2026. The encouraging six-month findings leave longer-term safety and eventual approval unresolved.
$BAND ( ▲ 9.09% ) : Bandwidth, Russell 2000 No. 25 → 22: A 9.1% weekly gain puts Thursday’s Oct. 29 earnings in focus. Its Salesforce Contact Center collaboration supports expansion across more than 25 countries. Risk: Converting that rollout into revenue remains the execution test; results and guidance will help investors judge the opportunity.
$AMN ( ▲ 2.54% ) : AMN Healthcare, Russell 2000 new No. 18: Shares gained 2.5% this week, extending their 204.6% yearly advance ahead of Nov. 5 earnings. Travel-nurse demand has been recovering. Risk: Its third-quarter outlook calls for adjusted EBITDA margins of 6.5%–7%, down from 10.9% in the second quarter, limiting how much improving demand translates into profit.
$MXL ( ▼ 2.79% ) : MaxLinear, Russell 2000 No. 7 → 11: Shares lost 2.8% this week despite 72% quarterly revenue growth. Its push into 1.6-terabit active electrical cables adds another growth opportunity. Risk: Management’s ambition to capture 20%–30% of that market centers on one or two large U.S. data-center customers, making customer wins critical.
Next week’s swing factor: The Fed’s Wednesday, Oct. 28 decision and Thursday’s PCE inflation report will test financing-sensitive biotech and growth stocks, alongside Bandwidth’s Thursday earnings.
Get In Touch 📬
Want to see some change? Respond to this email and reach me, Kevin Travers, with feedback. Follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎
How was this Issue of the Daily Rip?
📰📰📰 Great | 📰📰 Meh | 🗞️ What were you thinking?
Terms & Conditions 📝
Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋
